Deals

Back To Basics 2001-07-17 Staff Writer As the French say, plus ça change, plus ç’est la meme chose ('the more things change, the more they stay the same'). In 1988, when I wrote my first treatise on venture capital, I mentioned a phenomenon which had been apparent to me and other experienced players in this
IRegent, Jim Mellon’s Hong Kong investment group, provides initial backing for a new genetic medicine fund.
John Major will be the firm's European chairman. Christopher Finn explains why, and looks at other developments inside the firm.
Epartners has given back its e-money. The firm has decided it cannot invest $520m of the $650m fund it raised for internet companies last July and will return it to investors including Morgan Stanley and Softbank.
The venture capitalist has announced a $950m fund aimed at biotech and IT, but not the internet. Institutionals on both sides of the Atlantic contributed to the fund.
Money from Merlin Bioscience, Citigroup, Verus and 3i; initial close from Vertex.
Former analyst Michael Wand brings ‘deep insight into the software landscape' to the group.
Investors in the Scottish fund include Bank of Scotland, Old Mutual, Northern Rock Plc and Fortis Bank SA/NV.
Craig McCallum and Brian Aiken have been taken on as part of Protégé's expansion programme.
Global Equity Partners and Go Equity also participated in the round.
ii
ii

Copyright PEI Media

Not for publication, email or dissemination